Cargando…

Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series

AIM: Non-small-cell lung cancer recurs locally 10–40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients. METHODS: We identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegner, Rodney E, Ahmed, Nissar, Hasan, Shaakir, Schumacher, Lana Y, Colonias, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356147/
https://www.ncbi.nlm.nih.gov/pubmed/30713586
http://dx.doi.org/10.2217/lmt-2018-0012
Descripción
Sumario:AIM: Non-small-cell lung cancer recurs locally 10–40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients. METHODS: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy. RESULTS: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT. CONCLUSION: SBRT is safe and effective when used for re-irradiation after past ablative therapies.